Loading...
Loading...
Teva Pharmaceutical Industries Ltd.
TEVA today announced the
launch of the generic equivalent to ADENOSCAN® (adenosine injection) in
the United States. Teva was first to file, making the product eligible
for 180 days of marketing exclusivity.
ADENOSCAN® is supplied as 20 mL and 30 mL vials and is indicated as an
adjunct to thallium-201 myocardial perfusion scintigraphy in patients
unable to exercise adequately. Marketed by Astellas Pharma, ADENOSCAN®
had annual sales of approximately $65 million in the United States,
according to IMS data as of June 30, 2013.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in